AU6155686A - Pharmaceutical compositions consisting of acylated phospholipids - Google Patents
Pharmaceutical compositions consisting of acylated phospholipidsInfo
- Publication number
- AU6155686A AU6155686A AU61556/86A AU6155686A AU6155686A AU 6155686 A AU6155686 A AU 6155686A AU 61556/86 A AU61556/86 A AU 61556/86A AU 6155686 A AU6155686 A AU 6155686A AU 6155686 A AU6155686 A AU 6155686A
- Authority
- AU
- Australia
- Prior art keywords
- appropriate
- pharmaceutically acceptable
- phospholipid
- alkylene
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The compositions consist of a) a phospholipid of the formula <IMAGE> in which m is two or three, R1 and R2 are, independently of one another, alkyl, alkenyl or acyl each with 10 to 20 C atoms, and X is a direct bond, C1-C4-alkylene, C2-C4-alkenylene or C1-C4-alkylene or C2-C4-alkenylene substituted by hydroxyl, or a pharmaceutically acceptable salt thereof, b) a phospholipid of the formula <IMAGE> in which R3 and R4 are the acyl group of a saturated or unsaturated carboxylic acid with 10 to 20 C atoms and 1 to 2 double bonds, c) a compound or a mixture of compounds with pharmacological properties and, where appropriate, d) a lipid from the group comprising phosphatidylcholines, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, cardiolipin and cholesterol and, where appropriate, a pharmaceutically acceptable carrier solution which is buffered to pH 7.0 to 7.8 and, where appropriate, pharmaceutically acceptable auxiliaries. The compositions can be used in the form of liposomes as administration systems, for example for cancer chemotherapy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76662585A | 1985-08-19 | 1985-08-19 | |
| US766625 | 1985-08-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6155686A true AU6155686A (en) | 1987-02-26 |
| AU591162B2 AU591162B2 (en) | 1989-11-30 |
Family
ID=25077017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61556/86A Ceased AU591162B2 (en) | 1985-08-19 | 1986-08-18 | Pharmaceutical compositions consisting of acylated phospholipids |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0213523B1 (en) |
| JP (1) | JPS6296431A (en) |
| KR (1) | KR870001838A (en) |
| AT (1) | ATE59002T1 (en) |
| AU (1) | AU591162B2 (en) |
| CA (1) | CA1273575A (en) |
| DD (1) | DD248736A5 (en) |
| DE (1) | DE3676133D1 (en) |
| DK (1) | DK165314C (en) |
| ES (1) | ES2001099A6 (en) |
| FI (1) | FI863311A (en) |
| GR (1) | GR862144B (en) |
| HU (1) | HU206045B (en) |
| NO (1) | NO171886C (en) |
| NZ (1) | NZ217239A (en) |
| PH (1) | PH26160A (en) |
| PT (1) | PT83204B (en) |
| ZA (1) | ZA866200B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680513B2 (en) * | 1993-05-21 | 1997-07-31 | Liposome Company, Inc., The | Reduction of liposome-induced adverse physiological reactions |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0256989A1 (en) * | 1986-08-18 | 1988-02-24 | Board Of Regents, The University Of Texas System | Pharmaceutical administration systems containing chemotactic peptides |
| DK86988A (en) * | 1987-02-25 | 1988-08-26 | Takeda Chemical Industries Ltd | LIPOSOM PREPARATION AND APPLICATION THEREOF |
| AU7496991A (en) * | 1990-03-20 | 1991-10-21 | Otsuka Pharmaceutical Co., Ltd. | Liposome preparation |
| DK0785773T3 (en) * | 1994-10-14 | 2001-01-29 | Liposome Co Inc | Etherlipid liposomes and their therapeutic use |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
| US7306784B2 (en) | 1998-06-20 | 2007-12-11 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| WO2006026184A2 (en) | 2004-08-20 | 2006-03-09 | Washington University | Blood brain barrier permeation peptides |
| JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
| US20200197547A1 (en) | 2017-08-30 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3218027A1 (en) * | 1982-05-13 | 1983-11-17 | A. Nattermann & Cie GmbH, 5000 Köln | PHOSPHOLIPID SOLUTIONS |
-
1986
- 1986-07-18 PH PH34151A patent/PH26160A/en unknown
- 1986-08-14 PT PT83204A patent/PT83204B/en not_active IP Right Cessation
- 1986-08-15 CA CA000516015A patent/CA1273575A/en not_active Expired - Lifetime
- 1986-08-15 FI FI863311A patent/FI863311A/en not_active Application Discontinuation
- 1986-08-18 HU HU863618A patent/HU206045B/en not_active IP Right Cessation
- 1986-08-18 KR KR1019860006783A patent/KR870001838A/en not_active Application Discontinuation
- 1986-08-18 AT AT86111368T patent/ATE59002T1/en not_active IP Right Cessation
- 1986-08-18 NZ NZ217239A patent/NZ217239A/en unknown
- 1986-08-18 DE DE8686111368T patent/DE3676133D1/en not_active Expired - Lifetime
- 1986-08-18 ZA ZA866200A patent/ZA866200B/en unknown
- 1986-08-18 GR GR862144A patent/GR862144B/en unknown
- 1986-08-18 JP JP61191795A patent/JPS6296431A/en active Pending
- 1986-08-18 ES ES8601163A patent/ES2001099A6/en not_active Expired
- 1986-08-18 EP EP86111368A patent/EP0213523B1/en not_active Expired - Lifetime
- 1986-08-18 AU AU61556/86A patent/AU591162B2/en not_active Ceased
- 1986-08-18 DD DD86293707A patent/DD248736A5/en not_active IP Right Cessation
- 1986-08-18 DK DK392786A patent/DK165314C/en not_active IP Right Cessation
- 1986-08-18 NO NO863315A patent/NO171886C/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680513B2 (en) * | 1993-05-21 | 1997-07-31 | Liposome Company, Inc., The | Reduction of liposome-induced adverse physiological reactions |
Also Published As
| Publication number | Publication date |
|---|---|
| PH26160A (en) | 1992-03-18 |
| NZ217239A (en) | 1989-09-27 |
| ES2001099A6 (en) | 1988-04-16 |
| HU206045B (en) | 1992-08-28 |
| DE3676133D1 (en) | 1991-01-24 |
| CA1273575A (en) | 1990-09-04 |
| PT83204B (en) | 1989-03-30 |
| FI863311A (en) | 1987-02-20 |
| EP0213523A2 (en) | 1987-03-11 |
| JPS6296431A (en) | 1987-05-02 |
| EP0213523B1 (en) | 1990-12-12 |
| FI863311A0 (en) | 1986-08-15 |
| NO863315D0 (en) | 1986-08-18 |
| DD248736A5 (en) | 1987-08-19 |
| HUT41634A (en) | 1987-05-28 |
| DK165314B (en) | 1992-11-09 |
| NO171886B (en) | 1993-02-08 |
| NO863315L (en) | 1987-02-20 |
| DK392786D0 (en) | 1986-08-18 |
| EP0213523A3 (en) | 1987-10-14 |
| PT83204A (en) | 1986-09-01 |
| AU591162B2 (en) | 1989-11-30 |
| ZA866200B (en) | 1987-03-25 |
| DK165314C (en) | 1993-03-29 |
| KR870001838A (en) | 1987-03-28 |
| GR862144B (en) | 1986-12-23 |
| DK392786A (en) | 1987-02-20 |
| ATE59002T1 (en) | 1990-12-15 |
| NO171886C (en) | 1993-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU591162B2 (en) | Pharmaceutical compositions consisting of acylated phospholipids | |
| WO1990004918A3 (en) | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions | |
| ES474288A1 (en) | 3-Substituted-6-substituted-7-oxo-1-azabicyclo (3.2.0)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it. | |
| NZ223262A (en) | 11-arylestra-4,9-dien-3-ones, derivatives and pharmaceutical compositions | |
| AU639717B2 (en) | 24-homo vitamin d derivatives, process for their production and pharmaceutical preparations obtained therefrom | |
| HUT35957A (en) | Process for producing phosholipide compositions and pharmaceutical compositions containing them as active agents | |
| AU5791190A (en) | New peptide derivatives, process for preparing them and pharmaceutical compositions containing them | |
| IL87254A0 (en) | Stable oxapenem-3-carboxylic acids,their preparation and pharmaceutical compositions containing them | |
| NZ222741A (en) | Pharmaceutical compositions containing an interferon and a purine derivative | |
| ES8205224A1 (en) | 6-, 1- and 2-substituted-1-carbadethiapen-2-em-3-carboxylic acids, processes for preparing the same, pharmaceutical compositions containing the same, and intermediates. | |
| ES2087421T3 (en) | (1'S) -HYDROXIALKYLLOXAPENEM-3-CARBOXYLIC ACIDS AND THEIR USE AS AN INHIBITOR OF BETALACTAMASE. | |
| RU94042399A (en) | Preparation of clavulanic acid from clavulanic acid salt and amine, clavulanic acid and amine salts | |
| PT86422A (en) | PROCESS FOR THE PREPARATION OF DIBENZO] BE-OXEPINE-ACETIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |